Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims:

Claims 1-20. (Cancelled)

Claim 21. (new): A method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells comprising: providing a biological agent which binds to an outer membrane domain of prostate specific membrane antigen and contacting said cells with the biological agent under conditions effective to permit both binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen and ablating or killing of said cells.

Claim 22. (new): A method according to claim 21, wherein the biological agent is an antibody or ligand.

Claim 23. (new): A method according to claim 21, wherein said contacting is carried out in a living mammal and comprises: administering the biological agent to the mammal under conditions effective to permit both binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen and killing of said cells.

Claim 24. (new): A method according to claim 23, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously or

intramuscularly.

Claim 25. (new): A method according to claim 22, wherein an antibody is used in carrying out said method, the antibody being selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

Claim 26. (new): A method according to claim 22, wherein the ligand is used in carrying out said method.

Claim 27. (new): A method according to claim 21, wherein the biological agent is bound to a substance effective to kill or ablate said cells upon binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen of said cells.

Claim 28. (new): A method according to claim 27, wherein the substance effective to kill said cells is a cytotoxic agent.

Claim 29. (new): A method according to claim 28, wherein the cytotoxic agent is selected from the group consisting of a drug, a toxin, a radioactive substance, a chemotherapeutic, an enzyme and molecules of fungal, viral and bacterial origin.

Claim 30. (new): A method according to claim 21, wherein the biological agent is in a composition further comprising a physiologically acceptable carrier, diluent, or stabilizer.

Claim 31. (new): A method according to claim 21, wherein the

biological agent is in a composition further comprising a pharmaceutically acceptable carrier, diluent, or stabilizer.

Claim 32. (new): A method of detecting normal, benign hyperplastic, and cancerous prostate epithelial cells or a portion thereof in a biological sample comprising: providing a biological agent which binds to an outer membrane domain of prostate specific membrane antigen, wherein the biological agent is bound to a label effective to permit detection of said cells or a portion thereof upon binding of the biological agent to said cells or a portion thereof; contacting the biological sample with the biological agent having a label under conditions effective to permit binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen of any of said cells or a portion thereof in the biological sample; and detecting a presence of any of said cells or a portion thereof in the biological sample by detecting the label.

Claim 33. (new): A method according to claim 32, wherein the biological agent is an antibody or ligand.

Claim 34. (new): A method according to claim 32, wherein said contacting is carried out in a living mammal and comprises: administering the biological agent to the mammal under conditions effective to permit binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen of any of said cells or a portion thereof in the biological sample.

Claim 35. (new): A method according to claim 34, wherein the label is a radioactive substance.

Claim 36. (new): A method according to claim 34, wherein the biological sample is a mammal's prostatic tissue.

Claim 37. (new): A method according to claim 34, wherein said detecting is carried out after a prostatectomy.

Claim 38. (new): A method according to claim 34, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously or intramuscularly.

Claim 39. (new): A method according to claim 33, wherein an antibody is used in carrying out said method, said antibody being selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

Claim 40. (new): A method according to claim 33, wherein a ligand is used in carrying out said method.

Claim 41. (new): A method according to claim 32, wherein the label is selected from the group consisting of a fluorescent label and a radioactive label.

Claim 42. (new): A method according to claim 32, wherein the biological agent is in a composition further comprising a physiologically acceptable carrier, diluent, or stabilizer.

biological agent is in a composition further comprising a pharmaceutically acceptable carrier, diluent, or stabilizer.

Claim 44. (new): A method according to claim 32, wherein said contacting is carried out in a sample of serum or urine.

Claim 45. (new): An isolated biological agent which binds to an outer membrane domain of prostate specific membrane antigen.

Claim 46. (new): An isolated biological agent according to claim 45, wherein said isolated biological agent is an isolated antibody or ligand.

Claim 47. (new): An isolated biological agent according to claim 46, wherein the isolated biological agent is an antibody selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

Claim 48. (new): An isolated biological agent according to claim 46, wherein the isolated biological agent is a ligand.

Claim 49. (new): An isolated biological agent according to claim 45, wherein the biological agent is bound to a cytotoxic agent.

Claim 50. (new): An isolated biological agent according to claim 49, wherein the cytotoxic agent is selected from the group consisting of a drug, a toxin, a radioactive substance, a chemotherapeutic, and molecules of fungal, viral and bacterial origin.

Claim 51. (new): A composition comprising: a biological agent according to claim 49 and a physiologically acceptable carrier, diluent, or stabilizer mixed with the biological agent.

Claim 52. (new): A composition comprising: a biological agent according to claim 49 and a pharmaceutically acceptable carrier, diluent, or stabilizer mixed with the biological agent.

Claim 53. (new): An isolated biological agent according to claim 45, wherein said biological agent is bound to a label.

Claim 54. (new): An isolated biological agent according to claim 53, wherein the label is selected from the group consisting of a fluorescent label, a radioactive label and an immunohistochemical probe.

Claim 55. (new): An isolated biological agent according to claim 45, wherein said biological agent is bound to a biologically active enzyme.

Claim 56. (new): A composition comprising: a biological agent according to claim 53 and a physiologically acceptable carrier, diluent, or stabilizer mixed with the biological agent.

Claim 57. (new): A composition comprising: a biological agent according to claim 53 and a pharmaceutically acceptable carrier, diluent, or stabilizer mixed with the biological agent.

Claim 58. (new): A hybridoma cell line that produces a monoclonal antibody which binds to an outer membrane domain of prostate specific membrane antigen.